Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL

Clinical trial NCT05390749 · UNKNOWN

Trial details

NCT number: NCT05390749
Sponsor: Peking Union Medical College Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Central Nervous System Lymphoma

Start date: 2022-04-11
Primary completion: 2024-04-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.